COMMUNIQUÉS West-GlobeNewswire

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
01/05/2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Roquette finalise l’acquisition d’IFF Pharma Solutions
01/05/2025
Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la [...]
Roquette Completes the Acquisition of IFF Pharma Solutions
01/05/2025
Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the [...]
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
01/05/2025
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio , a biopharmaceutical company [...]
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
01/05/2025
Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 [...]
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
01/05/2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
01/05/2025
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s [...]
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
01/05/2025
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA- [...]
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
01/05/2025
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read [...]
SurgiBox Announces Strategic Partnership with BestBrick Medical in Taiwan
01/05/2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- SurgiBox, Inc., a pioneering medical technology company dedicated to bringing safe surgery to every patient, today announced a strategic partnership with BestBrick [...]
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
01/05/2025
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today [...]
FORM 8.1(a) & (b) - Mural Oncology plc
30/04/2025
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE [...]
FSR Celebrates Congressional Recognition of April as Sarcoidosis Awareness Month
30/04/2025
Announcement coincides with Foundation’s 25th anniversary and recent FMLA clarification supporting clinical trial access CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) today [...]
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
30/04/2025
WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility [...]
Mdxhealth to Release First Quarter 2025 Financial Results on May 14
30/04/2025
Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, [...]
DBV Technologies publie ses résultats financiers du 1er trimestre 2025
30/04/2025
Châtillon, France, le 30 avril (22 :00 CEST) 2025 DBV Technologies publie ses résultats financiers du 1er trimestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : [...]
DBV Technologies Reports First Quarter 2025 Financial Results
30/04/2025
Châtillon, France, April 30, 2025 DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage [...]
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires
30/04/2025
Daix (France), New York City (New York, Etats-Unis), le 30 avril 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique [...]
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
30/04/2025
Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies [...]

Pages